Slow-releasing ophthalmic compositions comprising povidone iodine
Inventors
Liang, Bo • Baldwin, John J. • Lu, Yong
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9308173-B2
Publication Date
2016-04-12
Expiration Date
Abstract
The present invention provides novel slow-releasing ophthalmic compositions containing Povidone Iodine (PVP-I) and uses thereof in the treatment of acute infections of at least one eye tissue from bacterial, mycobacterial, viral, fungal, or amoebic causes and for preventing such infections in appropriate clinical settings. Each of the ophthalmic compositions contains povidone iodine, osmotic pressure regulator, suspending agent and EDTA-Na, wherein povidone iodine exists as microsphere particles formed by PVP-I and sodium alginate.
Core Innovation
The invention relates to an ophthalmic composition for treatment or prophylaxis of a disorder of at least one eye tissue. The composition comprises pharmaceutically acceptable excipients and povidone iodine (PVP-I), wherein PVP-I exists as microspheres formed by PVP-I and sodium alginate and cured by calcium chloride. The microspheres are presented as a slow-releasing ocular formulation based on the PVP-I/sodium alginate system cured with calcium chloride.
The disclosed composition is further characterized by microsphere formulation parameters and ranges, including PVP-I concentration, microsphere size, PVP-I:sodium alginate weight ratio, and microsphere loading. The composition optionally includes excipients such as osmotic pressure regulators, suspending agents, and EDTA-Na. These structural and compositional features support slow release in ocular conditions.
The disclosed system is positioned for ocular delivery with improved stability and release behavior. The partial content states long stability, including under light and acidic environments, and controlled release in neutral pH. Example studies in the partial content include microsphere dissolution in artificial tears and accelerated stability, as well as the role of calcium chloride with PVP-I in stabilizing the microspheres and pH-dependent behavior.
Claims Coverage
The independent claim covers an ophthalmic composition for treatment or prophylaxis of a disorder of at least one eye tissue, defined by PVP-I present as calcium chloride-cured microspheres formed from PVP-I and sodium alginate, combined with pharmaceutically acceptable excipients. At least one inventive feature is the specific microsphere formation and curing approach.
Ophthalmic composition with PVP-I microspheres formed from PVP-I and sodium alginate and cured by calcium chloride
An ophthalmic composition for treatment or prophylaxis of a disorder of at least one eye tissue, comprising pharmaceutically acceptable excipients and povidone iodine (PVP-I) wherein PVP-I exists as microspheres formed by PVP-I and sodium alginate and cured by calcium chloride.
The main inventive concept is the use of PVP-I as calcium chloride-cured microspheres formed from PVP-I and sodium alginate within an ophthalmic composition for treating or prophylaxis of an eye-tissue disorder, with pharmaceutically acceptable excipients.
Stated Advantages
Long stability, including under light and acidic environments.
Controlled/slow release in neutral pH.
Documented Applications
Treatment or prophylaxis of disorders of at least one eye tissue, including ocular infections and keratitis/conjunctivitis-related disorders.
Treatment or prophylaxis of ocular infections including bacterial, mycobacterial, viral, fungal, and amoebic infections.
Treatment or prophylaxis of keratitis and conjunctivitis-related disorders, including herpesvirus-related keratitis and ulcerative infectious keratitis.
Interested in licensing this patent?